Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wiegand

Showing results (251-260 of 267) with videos related to

Pageof 27
Sort By:
Developmental Cell|October 4, 2002
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1Nicholas W Gale, Gavin Thurston, Sean F Hackett, et al.
Science (New York, N.Y.)|July 4, 1997
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesisP C Maisonpierre, C Suri, P F Jones, et al.
Pain|March 24, 2007
Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responsesRichard Torres, Susan D Croll, Jeffrey Vercollone, et al.
Journal of Viral Hepatitis|December 17, 2013
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trialJ Wiegand, H Wedemeyer, A Franke, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2005
Resistance to diet-induced obesity in mice globally overexpressing OGH/GPB5Lynn E Macdonald, Katherine E Wortley, Lori C Gowen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2002
VEGF-Trap: a VEGF blocker with potent antitumor effectsJocelyn Holash, Sam Davis, Nick Papadopoulos, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Nature Methods|March 3, 2015
Highly efficient Cas9-mediated transcriptional programmingAlejandro Chavez, Jonathan Scheiman, Suhani Vora, et al.
Journal of Viral Hepatitis|June 3, 2009
Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resourcesJ Wiegand, B Luz, A-K Mengelkamp, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|April 19, 2011
Quality management in the prophylaxis of venous thrombembolism--results of a survey including 464 medical and surgical patientsP Klein-Weigel, J Richter, U Arendt, et al.
Pageof 27

Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
Developmental Cell|October 4, 2002
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1Nicholas W Gale, Gavin Thurston, Sean F Hackett, et al.
Science (New York, N.Y.)|July 4, 1997
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesisP C Maisonpierre, C Suri, P F Jones, et al.
Pain|March 24, 2007
Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responsesRichard Torres, Susan D Croll, Jeffrey Vercollone, et al.
Journal of Viral Hepatitis|December 17, 2013
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trialJ Wiegand, H Wedemeyer, A Franke, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2005
Resistance to diet-induced obesity in mice globally overexpressing OGH/GPB5Lynn E Macdonald, Katherine E Wortley, Lori C Gowen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2002
VEGF-Trap: a VEGF blocker with potent antitumor effectsJocelyn Holash, Sam Davis, Nick Papadopoulos, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Nature Methods|March 3, 2015
Highly efficient Cas9-mediated transcriptional programmingAlejandro Chavez, Jonathan Scheiman, Suhani Vora, et al.
Journal of Viral Hepatitis|June 3, 2009
Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resourcesJ Wiegand, B Luz, A-K Mengelkamp, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|April 19, 2011
Quality management in the prophylaxis of venous thrombembolism--results of a survey including 464 medical and surgical patientsP Klein-Weigel, J Richter, U Arendt, et al.
Pageof 27